Home Semiconductor & Electronics Electronic Components SGLT2 Inhibitors Market

SGLT2 Inhibitors Market Size, Share & Trends Analysis Report By Drug (Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin, Ipragliflozin, Sotagliflozin, Others), By Indication (Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease, Weight Management, Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Pharmacies) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: December 23, 2025 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. SGLT2 Inhibitors Market, By Drug 2022-2034 (USD MILLION/ Units)
    1. Canagliflozin
    2. Dapagliflozin
    3. Empagliflozin
    4. Ertugliflozin
    5. Ipragliflozin
    6. Sotagliflozin
    7. Others
  2. SGLT2 Inhibitors Market, By Indication 2022-2034 (USD MILLION/ Units)
    1. Type 2 Diabetes
    2. Cardiovascular
    3. Chronic Kidney Disease 
    4. Weight Management
    5. Others
  3. SGLT2 Inhibitors Market, By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. Online Pharmacies
  4. Regional SGLT2 Inhibitors Market
    1. North America
      1. North America SGLT2 Inhibitors Market By Drug 2022-2034 (USD MILLION/ Units)
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
      2. North America SGLT2 Inhibitors Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes
        2. Cardiovascular
        3. Chronic Kidney Disease 
        4. Weight Management
        5. Others
      3. North America SGLT2 Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
      4. U.S.
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
        8. Type 2 Diabetes
        9. Cardiovascular
        10. Chronic Kidney Disease 
        11. Weight Management
        12. Others
        13. Hospital Pharmacies
        14. Drug Stores & Retail Pharmacies
        15. Online Pharmacies
      5. Canada
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
        8. Type 2 Diabetes
        9. Cardiovascular
        10. Chronic Kidney Disease 
        11. Weight Management
        12. Others
        13. Hospital Pharmacies
        14. Drug Stores & Retail Pharmacies
        15. Online Pharmacies
    2. Europe
      1. Europe SGLT2 Inhibitors Market By Drug 2022-2034 (USD MILLION/ Units)
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
      2. Europe SGLT2 Inhibitors Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes
        2. Cardiovascular
        3. Chronic Kidney Disease 
        4. Weight Management
        5. Others
      3. Europe SGLT2 Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
      4. U.K.
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
        8. Type 2 Diabetes
        9. Cardiovascular
        10. Chronic Kidney Disease 
        11. Weight Management
        12. Others
        13. Hospital Pharmacies
        14. Drug Stores & Retail Pharmacies
        15. Online Pharmacies
      5. Germany
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
        8. Type 2 Diabetes
        9. Cardiovascular
        10. Chronic Kidney Disease 
        11. Weight Management
        12. Others
        13. Hospital Pharmacies
        14. Drug Stores & Retail Pharmacies
        15. Online Pharmacies
      6. France
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
        8. Type 2 Diabetes
        9. Cardiovascular
        10. Chronic Kidney Disease 
        11. Weight Management
        12. Others
        13. Hospital Pharmacies
        14. Drug Stores & Retail Pharmacies
        15. Online Pharmacies
      7. Spain
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
        8. Type 2 Diabetes
        9. Cardiovascular
        10. Chronic Kidney Disease 
        11. Weight Management
        12. Others
        13. Hospital Pharmacies
        14. Drug Stores & Retail Pharmacies
        15. Online Pharmacies
      8. Italy
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
        8. Type 2 Diabetes
        9. Cardiovascular
        10. Chronic Kidney Disease 
        11. Weight Management
        12. Others
        13. Hospital Pharmacies
        14. Drug Stores & Retail Pharmacies
        15. Online Pharmacies
      9. Russia
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
        8. Type 2 Diabetes
        9. Cardiovascular
        10. Chronic Kidney Disease 
        11. Weight Management
        12. Others
        13. Hospital Pharmacies
        14. Drug Stores & Retail Pharmacies
        15. Online Pharmacies
      10. Nordic
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
        8. Type 2 Diabetes
        9. Cardiovascular
        10. Chronic Kidney Disease 
        11. Weight Management
        12. Others
        13. Hospital Pharmacies
        14. Drug Stores & Retail Pharmacies
        15. Online Pharmacies
      11. Benelux
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
        8. Type 2 Diabetes
        9. Cardiovascular
        10. Chronic Kidney Disease 
        11. Weight Management
        12. Others
        13. Hospital Pharmacies
        14. Drug Stores & Retail Pharmacies
        15. Online Pharmacies
      12. Rest of Europe
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
        8. Type 2 Diabetes
        9. Cardiovascular
        10. Chronic Kidney Disease 
        11. Weight Management
        12. Others
        13. Hospital Pharmacies
        14. Drug Stores & Retail Pharmacies
        15. Online Pharmacies
    3. APAC
      1. APAC SGLT2 Inhibitors Market By Drug 2022-2034 (USD MILLION/ Units)
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
      2. APAC SGLT2 Inhibitors Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes
        2. Cardiovascular
        3. Chronic Kidney Disease 
        4. Weight Management
        5. Others
      3. APAC SGLT2 Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
      4. China
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
        8. Type 2 Diabetes
        9. Cardiovascular
        10. Chronic Kidney Disease 
        11. Weight Management
        12. Others
        13. Hospital Pharmacies
        14. Drug Stores & Retail Pharmacies
        15. Online Pharmacies
      5. Korea
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
        8. Type 2 Diabetes
        9. Cardiovascular
        10. Chronic Kidney Disease 
        11. Weight Management
        12. Others
        13. Hospital Pharmacies
        14. Drug Stores & Retail Pharmacies
        15. Online Pharmacies
      6. Japan
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
        8. Type 2 Diabetes
        9. Cardiovascular
        10. Chronic Kidney Disease 
        11. Weight Management
        12. Others
        13. Hospital Pharmacies
        14. Drug Stores & Retail Pharmacies
        15. Online Pharmacies
      7. India
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
        8. Type 2 Diabetes
        9. Cardiovascular
        10. Chronic Kidney Disease 
        11. Weight Management
        12. Others
        13. Hospital Pharmacies
        14. Drug Stores & Retail Pharmacies
        15. Online Pharmacies
      8. Australia
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
        8. Type 2 Diabetes
        9. Cardiovascular
        10. Chronic Kidney Disease 
        11. Weight Management
        12. Others
        13. Hospital Pharmacies
        14. Drug Stores & Retail Pharmacies
        15. Online Pharmacies
      9. Taiwan
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
        8. Type 2 Diabetes
        9. Cardiovascular
        10. Chronic Kidney Disease 
        11. Weight Management
        12. Others
        13. Hospital Pharmacies
        14. Drug Stores & Retail Pharmacies
        15. Online Pharmacies
      10. South East Asia
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
        8. Type 2 Diabetes
        9. Cardiovascular
        10. Chronic Kidney Disease 
        11. Weight Management
        12. Others
        13. Hospital Pharmacies
        14. Drug Stores & Retail Pharmacies
        15. Online Pharmacies
      11. Rest of Asia-Pacific
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
        8. Type 2 Diabetes
        9. Cardiovascular
        10. Chronic Kidney Disease 
        11. Weight Management
        12. Others
        13. Hospital Pharmacies
        14. Drug Stores & Retail Pharmacies
        15. Online Pharmacies
    4. Middle East and Africa
      1. Middle East and Africa SGLT2 Inhibitors Market By Drug 2022-2034 (USD MILLION/ Units)
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
      2. Middle East and Africa SGLT2 Inhibitors Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes
        2. Cardiovascular
        3. Chronic Kidney Disease 
        4. Weight Management
        5. Others
      3. Middle East and Africa SGLT2 Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
      4. UAE
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
        8. Type 2 Diabetes
        9. Cardiovascular
        10. Chronic Kidney Disease 
        11. Weight Management
        12. Others
        13. Hospital Pharmacies
        14. Drug Stores & Retail Pharmacies
        15. Online Pharmacies
      5. Turkey
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
        8. Type 2 Diabetes
        9. Cardiovascular
        10. Chronic Kidney Disease 
        11. Weight Management
        12. Others
        13. Hospital Pharmacies
        14. Drug Stores & Retail Pharmacies
        15. Online Pharmacies
      6. Saudi Arabia
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
        8. Type 2 Diabetes
        9. Cardiovascular
        10. Chronic Kidney Disease 
        11. Weight Management
        12. Others
        13. Hospital Pharmacies
        14. Drug Stores & Retail Pharmacies
        15. Online Pharmacies
      7. South Africa
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
        8. Type 2 Diabetes
        9. Cardiovascular
        10. Chronic Kidney Disease 
        11. Weight Management
        12. Others
        13. Hospital Pharmacies
        14. Drug Stores & Retail Pharmacies
        15. Online Pharmacies
      8. Egypt
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
        8. Type 2 Diabetes
        9. Cardiovascular
        10. Chronic Kidney Disease 
        11. Weight Management
        12. Others
        13. Hospital Pharmacies
        14. Drug Stores & Retail Pharmacies
        15. Online Pharmacies
      9. Nigeria
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
        8. Type 2 Diabetes
        9. Cardiovascular
        10. Chronic Kidney Disease 
        11. Weight Management
        12. Others
        13. Hospital Pharmacies
        14. Drug Stores & Retail Pharmacies
        15. Online Pharmacies
      10. Rest of MEA
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
        8. Type 2 Diabetes
        9. Cardiovascular
        10. Chronic Kidney Disease 
        11. Weight Management
        12. Others
        13. Hospital Pharmacies
        14. Drug Stores & Retail Pharmacies
        15. Online Pharmacies
    5. LATAM
      1. LATAM SGLT2 Inhibitors Market By Drug 2022-2034 (USD MILLION/ Units)
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
      2. LATAM SGLT2 Inhibitors Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes
        2. Cardiovascular
        3. Chronic Kidney Disease 
        4. Weight Management
        5. Others
      3. LATAM SGLT2 Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
      4. Brazil
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
        8. Type 2 Diabetes
        9. Cardiovascular
        10. Chronic Kidney Disease 
        11. Weight Management
        12. Others
        13. Hospital Pharmacies
        14. Drug Stores & Retail Pharmacies
        15. Online Pharmacies
      5. Mexico
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
        8. Type 2 Diabetes
        9. Cardiovascular
        10. Chronic Kidney Disease 
        11. Weight Management
        12. Others
        13. Hospital Pharmacies
        14. Drug Stores & Retail Pharmacies
        15. Online Pharmacies
      6. Argentina
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
        8. Type 2 Diabetes
        9. Cardiovascular
        10. Chronic Kidney Disease 
        11. Weight Management
        12. Others
        13. Hospital Pharmacies
        14. Drug Stores & Retail Pharmacies
        15. Online Pharmacies
      7. Chile
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
        8. Type 2 Diabetes
        9. Cardiovascular
        10. Chronic Kidney Disease 
        11. Weight Management
        12. Others
        13. Hospital Pharmacies
        14. Drug Stores & Retail Pharmacies
        15. Online Pharmacies
      8. Colombia
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
        8. Type 2 Diabetes
        9. Cardiovascular
        10. Chronic Kidney Disease 
        11. Weight Management
        12. Others
        13. Hospital Pharmacies
        14. Drug Stores & Retail Pharmacies
        15. Online Pharmacies
      9. Rest of LATAM
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
        8. Type 2 Diabetes
        9. Cardiovascular
        10. Chronic Kidney Disease 
        11. Weight Management
        12. Others
        13. Hospital Pharmacies
        14. Drug Stores & Retail Pharmacies
        15. Online Pharmacies
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.